Genomictree Inc.
Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect … Read more
Genomictree Inc. (228760) - Net Assets
Latest net assets as of September 2025: ₩115.95 Billion KRW
Based on the latest financial reports, Genomictree Inc. (228760) has net assets worth ₩115.95 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩122.89 Billion) and total liabilities (₩6.94 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩115.95 Billion |
| % of Total Assets | 94.35% |
| Annual Growth Rate | 6.88% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 11.61 |
Genomictree Inc. - Net Assets Trend (2020–2024)
This chart illustrates how Genomictree Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Genomictree Inc. (2020–2024)
The table below shows the annual net assets of Genomictree Inc. from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩124.32 Billion | -0.57% |
| 2023-12-31 | ₩125.03 Billion | +16.79% |
| 2022-12-31 | ₩107.05 Billion | -6.99% |
| 2021-12-31 | ₩115.10 Billion | +20.83% |
| 2020-12-31 | ₩95.26 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Genomictree Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5291204607000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩20.60 Billion | 16.63% |
| Common Stock | ₩12.18 Billion | 9.83% |
| Other Components | ₩91.10 Billion | 73.54% |
| Total Equity | ₩123.88 Billion | 100.00% |
Genomictree Inc. Competitors by Market Cap
The table below lists competitors of Genomictree Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Turners Automotive Group Ltd
AU:TRA
|
$278.21 Million |
|
Jinan High tech Development Co Ltd
SHG:600807
|
$278.27 Million |
|
Upstream Bio, Inc.
NASDAQ:UPB
|
$278.33 Million |
|
Jw Pharmac
KO:001060
|
$278.34 Million |
|
Gruvaktiebolaget Viscaria
ST:VISC
|
$278.06 Million |
|
Jyothy Labs Limited
NSE:JYOTHYLAB
|
$278.06 Million |
|
Beijing Haohan Data Technology Co. Ltd. A
SHG:688292
|
$278.06 Million |
|
Hangzhou Haoyue Personal Care Co Ltd
SHG:605009
|
$277.99 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genomictree Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 124,736,301,070 to 123,884,817,630, a change of -851,483,440 (-0.7%).
- Net loss of 10,242,377,380 reduced equity.
- Other factors increased equity by 9,390,893,940.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-10.24 Billion | -8.27% |
| Other Changes | ₩9.39 Billion | +7.58% |
| Total Change | ₩- | -0.68% |
Book Value vs Market Value Analysis
This analysis compares Genomictree Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.90x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 4.23x to 3.90x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | ₩4766.06 | ₩20150.00 | x |
| 2021-12-31 | ₩5662.32 | ₩20150.00 | x |
| 2022-12-31 | ₩5185.29 | ₩20150.00 | x |
| 2023-12-31 | ₩5278.29 | ₩20150.00 | x |
| 2024-12-31 | ₩5163.99 | ₩20150.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genomictree Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8.27%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -433.57%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.05x
- Recent ROE (-8.27%) is above the historical average (-8.76%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -12.38% | -952.10% | 0.01x | 1.24x | ₩-21.32 Billion |
| 2021 | -9.93% | -222.28% | 0.03x | 1.54x | ₩-22.93 Billion |
| 2022 | -6.19% | -22.20% | 0.18x | 1.52x | ₩-17.34 Billion |
| 2023 | -7.02% | -256.17% | 0.03x | 1.06x | ₩-21.23 Billion |
| 2024 | -8.27% | -433.57% | 0.02x | 1.05x | ₩-22.63 Billion |
Industry Comparison
This section compares Genomictree Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genomictree Inc. (228760) | ₩115.95 Billion | -12.38% | 0.06x | $278.07 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |